Loading…
← CockpitCompetitor Analysis › 300705.SZ Hunan Jiudian Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Hunan Jiudian Pharmaceutical Co. Ltd. Class A300705.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 58
Mkt cap
$738M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$6.44M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
+6.2 pp
WACC 6.2%
Hurdle
-28 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥9.89
1D-1.4%
1W-5.0%
1M-8.4%
3M-15.4%
6M-19.7%
YTD-34.0%
1Y-39.6%
ATR %2.7%
52w lowhigh43.1% off high

What Hunan Jiudian Pharmaceutical does

Employees: 2,298

Hunan Jiudian Pharmaceutical at a glance

Size Hunan Jiudian Pharmaceutical (300705.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $738M, the 2774th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.89 on 18 Nov 2026.

Performance Over six months the shares fell 19.7%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue fell 5.3% over the last twelve months (peer median +3.5%); the operating margin is 12.9% (peer median 8.8%).

Valuation It trades at 16.7× forward earnings against a peer median of 13.7× (2nd most expensive of 6).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -28 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.2 points above its cost of capital (6.2% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 93300705.SZ 82
Six months, rebased to 100: Hunan Jiudian Pharmaceutical against the median of its 20 peers (local-currency closes).

Hunan Jiudian Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.89BCN¥3.09BCN¥2.91BCN¥2.67BCN¥2.31B
Revenue growth—+6%+9%+16%—
Gross profitCN¥1.92BCN¥2.20BCN¥2.09BCN¥2.02BCN¥1.76B
EBITDAn/aCN¥669MCN¥637MCN¥442MCN¥338M
Net incomeCN¥306MCN¥473MCN¥512MCN¥368MCN¥270M
Free cash flowCN¥137M-CN¥3.11MCN¥352MCN¥6.46M-CN¥142M
Capital expenditureCN¥537MCN¥653MCN¥398MCN¥427MCN¥413M
Total debtCN¥799MCN¥595MCN¥357MCN¥430MCN¥369M

Quarterly statements and history in the cockpit →

Hunan Jiudian Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%21866004796885666005306887992171002907SGMT603998057045343001LXRX002390BLISSGVSNVCT300705.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hunan Jiudian Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-5%0%+5%+10%+15%20×40×21866885666887996039984534300705.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hunan Jiudian Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%21866004796885666005300029070024246039983001002390600829BLISSGVS300705.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hunan Jiudian Pharmaceutical is the large dot.

Hunan Jiudian Pharmaceutical competitors and peer comparison

How Hunan Jiudian Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hunan Jiudian Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300705.SZPeer medianRank in peer set
1-month return-8.4%-2.4%7th lowest of 20
6-month return-19.7%-7.3%9th lowest of 20
Distance from 52-week high-43.1%-33.7%5th lowest of 20
Revenue growth (TTM)-5.3%+3.5%5th lowest of 19
Operating margin12.9%8.8%6th highest of 19
Forward P/E16.7×13.7×2nd most expensive of 6
Growth the price implies (Req g, 7 yrs)-2.0%4.0%5th least demanding of 12
Growth delivered (Del g)+26.1%+0.5%highest of 12
Hurdle (Req g minus delivered)-28.1 pp-1.4 ppleast demanding of 12
ROIC minus cost of capital+6.2 pp+0.1 pp2nd highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a

Questions

Which companies are Hunan Jiudian Pharmaceutical's closest peers?
The cockpit's peer set: Luye Pharma (2186.HK), Zhuzhou Qianjin Pharmaceutical (600479.SS), Jiangsu Jibeier Pharmaceutical (688566.SS), Shanghai Jiaoda Onlly (600530.SS), Hunan Warrant Pharmaceutical (688799.SS), CARsgen Therapeutics (2171.HK), Chongqing Pharscin Pharmaceutical (002907.SZ), Sagimet Biosciences (SGMT).
Is Hunan Jiudian Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 13.7×, 2nd most expensive of 6 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -28 pp: the price already allows for a slowdown.
How has Hunan Jiudian Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -19.7% against -7.3% for the median peer; over one year -39.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.